Benjamin Heyman
Associate Clinical Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Dr. Benjamin Heyman is an Assistant Professor at the University of California San Diego, specializing in hematologic malignancies. His recent research includes innovative treatments for chronic lymphocytic leukemia, Hodgkin lymphoma, and targeted therapies for various lymphoid malignancies. Dr. Heyman's contributions to the field are underscored by his exploration of novel combination approaches and the efficacy of antibody therapies.
Articles (12)
Year:
2026
Introduction Bruton tyrosine kinase inhibitors (BTKi) are highly effective therapy for chronic lymphocytic leukemia (CLL) but can lead to long‐term side effects. Methods We performed a retrospective analysis of venetoclax consolidation of 20 patients with CLL after initial BTKi discontinuation. Patients were administered either single‐agent venetoclax or in combination with obinutuzumab. Results The best peripheral blood minimal residual disease (MRD) response was undetectable MRD, occurring in 89% of patients. With a median follow‐up of 47.4 months, both the median progression‐free survival and time‐to‐next treatment were not reached. Conclusion Venetoclax consolidation after BTKi is a feasible treatment strategy for patients with CLL, with encouraging efficacy deserving further study. Clinical Trial Registration : N/A
Year:
2025
Richter’s syndrome (RS) or transformation of chronic lymphocytic leukemia (CLL) into a more aggressive lymphoma (e.g., diffuse large B cell lymphoma, DLBCL) is a distinct disease that portends an overall poor prognosis and remains a challenge for clinicians to identify and treat effectively. This review of the current literature focuses on the pathology, diagnosis, and management of Richter’s syndrome. Clonally related RS has been found to have a worse prognosis than unrelated disease and the genomic profile of DLBCL-RS differs from that of de novo DLBCL. The standard of care therapy for RS has historically been chemoimmunotherapy; consolidative stem cell transplants have a role in improving durability of disease response. Given generally poor response rates to chemotherapy, there have been recent investigations into combination treatments with immune checkpoint inhibitors and small molecule targeted therapies, which have had mixed results. Additional studies are evaluating the use of bispecific antibodies, chimeric antigen receptor T cell therapy, and antibody drug conjugates. RS remains difficult to manage; however, advancements in the understanding of the underlying pathology of transformation and continued investigations into new therapies demonstrate promise for the future.
Year:
2025
Antibody therapies are a crucial component of modern lymphoid malignancy treatment and an exciting area of active research. We performed a review of modern antibody therapies used in the treatment of lymphoid malignancies, with an emphasis on landmark studies and current directions. We describe the indications for rituximab, obinutuzumab, ADCs, and bispecific antibody therapies. Finally, we summarize early data from ongoing trials on emerging novel therapy combination regimens and discuss the role of machine learning in future therapy development.
Year:
2025
Hodgkin lymphoma variant of Richter’s transformation (HvRT) is a rare complication for patients with chronic lymphocytic leukemia (CLL), with an overall poor prognosis. We present the first known case series of patients with HvRT treated with the combination of brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A + AVD). In our series of 4 patients, two patients treated with A + AVD for HvRT had durable remissions of 40 and 42 months, while two patients had disease progression and ultimately died. Continued investigation into the optimal management for patients with HvRT is still needed.
Year:
2024
Treatment of hematologic malignancies with patient-derived anti-CD19 chimeric antigen receptor (CAR) T-cells has demonstrated long-term remissions for patients with otherwise treatment-refractory advanced leukemia and lymphoma. Conversely, CAR T-cell treatment of solid tumors, including advanced gastric cancer (GC), has proven more challenging due to on-target off-tumor toxicities, poor tumor T-cell infiltration, inefficient CAR T-cell expansion, immunosuppressive tumor microenvironments, and demanding preconditioning regimens. We report the exceptional results of autologous Claudin18.2-targeted CAR T cells (CT041) in a patient with metastatic GC, who had progressed on four lines of combined systemic chemotherapy and immunotherapy. After two CT041 infusions, the patient had target lesion complete response and sustained an 8-month overall partial response with only minimal ascites. Moreover, tumor-informed circulating tumor DNA (ctDNA) reductions coincided with rapid CAR T-cell expansion and radiologic response. No severe toxicities occurred, and the patient’s quality of life significantly improved. This experience supports targeting Claudin18.2-positive GC with CAR T-cell therapy and helps to validate ctDNA as a biomarker in CAR T-cell therapy. Clinical Insight: Claudin18.2-targeted CAR T cells can safely provide complete objective and ctDNA response in salvage metastatic GC.
Year:
2024
BRAF mutations are associated with a small number of hematologic malignancies, including hairy cell leukemia and histiocytic disorders. In addition, BRAF mutations have also been detected in low frequency in other B‐cell lymphomas, such as chronic lymphocytic leukemia and diffuse large B‐cell lymphoma, but never in mantle cell lymphoma (MCL). We present a case of a 69‐year‐old female with classic MCL harboring a BRAF N581S mutation. To our knowledge, this is the first reported case of any BRAF mutation in MCL.
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2022
Collaborators (1)
Patricia Young
University of California, Los Angeles
Make your next move.
Prepare your application
Review drafts before you send them.